Planet 13 Holdings (PLNH) Current Deferred Revenue (2021 - 2025)
Planet 13 Holdings' (PLNH) quarterly Current Deferred Revenue came in at $226627.0 in Q4 2025, down 90.72% year-on-year from $2.4 million in Q4 2024, and down 90.72% on a QoQ basis from $2.4 million in Q4 2024.
Planet 13 Holdings (PLNH) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Planet 13 Holdings (PLNH) has 5 years of Current Deferred Revenue data on file, last reported at $226627.0 in Q4 2025.
- On a quarterly basis, Current Deferred Revenue fell 90.72% year-over-year to $226627.0 in Q4 2025; TTM through Dec 2025 was $226627.0, a 90.72% decrease from a year earlier, with the FY2025 full-year figure at $226627.0, down 90.72% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $226627.0, down from $2.4 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for PLNH reached as high as $2.4 million in Q4 2024 and fell as low as $226627.0 in Q4 2025.
- Historically, Current Deferred Revenue has averaged $1.1 million across 5 years, with a median of $1.0 million in 2022.
- Across the five-year window, Current Deferred Revenue jumped 95.54% in 2024 and plunged 90.72% in 2025, its largest moves.
- Year by year, Current Deferred Revenue stood at $759060.0 in 2021, then jumped by 38.04% to $1.0 million in 2022, then rose by 19.17% to $1.2 million in 2023, then soared by 95.54% to $2.4 million in 2024, then plunged by 90.72% to $226627.0 in 2025.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $226627.0 in Q4 2025, $2.4 million in Q4 2024, and $1.2 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Planet 13 Holdings | 39.35 Mn | 23.09 Mn | 9.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 226,627.00 |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.05 Mn |
| Dec 31, 2021 | 759,060.00 |